eISSN 2508-3589
pISSN 2508-1926
pISSN 2508-1926
Characteristics of patients with diabetic papillopathy
Case 1 | Case 2 | Case 3 | |
---|---|---|---|
Systemic | |||
Age | 51 | 64 | 71 |
Sex | F | M | M |
Diabetes treatment | Oral medication + Insulin | Oral medication | Oral medication |
Duration of diabetes (years) | 15 | 20 | 16 |
Laterality | Both eye | Right | Right |
Ocular, before diabetic papillopathy | |||
Diabetic retinopathy | Severe NPDR | Not checked | Regressed PDR |
Cup-to-disc diameter ratio, before presentation or from contralateral eye, right eye/left eye | 0.25/0.26 | 0.21 | 0.3 |
Best-corrected visual acuity, right eye/left eye | Not checked | Not checked | Not checked |
HbA1c level | 16.8 | Not checked | Not checked |
Ocular, at presentation of diabetic papillopathy | |||
Diabetic retinopathy | Active PDR | Moderate NPDR | Regressed PDR |
Best-corrected visual acuity, decimal, right eye/left eye | 0.1/0.08 | 0.16/0.63 | 0.2/0.5 |
Macular edema | +/+ | + | + |
HbA1c level (%) | 10.9 | 9.3 | 10.6 |
Recent insulin use | + | - | - |
Creatine level (mg/dL) | 0.78 | 0.66 | 5.65 |
eGFR (MDRD) (mL/min/1.73 m2) | 79.5 | 121.5 | 10.03 |
Urine protein (mg/dL) | 612.9 | 48.5 | 351.5 |
Treatment | |||
Intravitreal bevacizumab injection | +/+ | ++ | - |
Panretinal Photocoagulation | +/+ | - | - |
Sub-Tenon Triamcinolone injection | +++/+ | - | + |
Intravitreal Triamcinolone injection | -/++ | - | - |
Interval from onset to regression of papilledema (months) | 6/6 | 5 | 2 |
Ocular, at final follow-up | |||
Interval between presentation and latest follow-up (months) | 48 | 11 | 48 |
Optic disc appearance | Pale/pale | Not pale | Not pale |
Best-corrected visual acuity, right eye/left eye | 0.06/0.125 | FC 50 cm/0.63 | 0.25/0.5 |
F = female; M = male; PDR = proliferative diabetic retinopathy; eGFR = estimated glomerular filtration rate; MDRD = modification of diet in renal disease; FC = finger count.